Cerebral Infarction Drugs Market Trends

Growth Drivers

• Worldwide Growing Prevalence of Sedentary Lifestyle – Lack of physical activity can have significant health consequences. A sedentary lifestyle is gradually becoming a part of the contemporary life of people, contributing to the rapid increase of dangerous diseases such as cardiovascular disease, diabetes, obesity, cerebrovascular disease, strokes, and so on. Therefore, the growing prevalence of a sedentary lifestyle is a significant factor anticipated to boost the market growth of cerebral infarction drugs in the coming years. Based on a report, an estimated 3.6 million people die each year as a consequence of lack of physical activity, which affects about 34% of the world's population under 15 years old.

• Rising Cases of Arterial Embolism - An arterial embolism is a clot (embolus) that has traveled from another part of the body and created an abrupt halt in blood flow to an organ or body part. Hence, the upsurge in arterial embolism is another significant factor that is estimated to proliferate the market growth in the coming years. Based on a clinical study, in non-hospitalized individuals, arterial embolism rates by 2022 varied from 0.07% (94% CI, 0.04-0.07) in the UK and Italy to 0.77% (95% CI, 0.78-0.81) in Spain. Whereas the arterial embolism rate in non-hospitalized patients in the Netherlands was around 0.9% (95% CI, 0.08-0.16), but it was 0.18% (95% CI, 0.11-0.24) in Germany. In Spain, the rate increased to around 3.09% (95% CI, 2.97-3.24) among Covid-19 patients who were hospitalized.

• Increasing Cases of Brain Aneurysms - A brain aneurysm, also known as a cerebral aneurysm, is a thickening in a weak artery in or near the brain. Though they can develop in any part of the brain, the majority of brain aneurysms form in the large arteries running down the base of the skull. Hence, the surge in brain aneurysm and its complexities is also increasing the stances of cerebral infarction, which is further estimated to spike the market growth in the forecast period. For instance, currently, in the United States, an estimated 6.7 million people have an unruptured cerebral aneurysm.

• Growing Ratio of Aged Population - According to the World Health Organization estimates, the world's population of adults aged 60 and more is expected to increase substantially by 2.1 million by 2050. Moreover, between 2020 and 2050, the number of persons aged 80 and more is expected to triple, hitting 426 million.

• Rising Ratio of Clinical Trials and Their Positive Outcomes – For instance, in February 2022, Acticor Biotech SA disclosed favorable results from its ACTIMIS Phase Ib/IIa clinical trial of glenzocimab as an add-on treatment to the recommended treatment for patients with acute ischemic stroke (AIS). The results demonstrated that the trial exceeded the primary outcome, proving glenzocimab's favorable effectiveness and safety.

Challenges

• Risk of Side Effects Associated with the Treatment – Several times, the associated side effects may occur during the treatment of ischemic stroke. Risks, such as the development of angioedema which is a life-threatening condition caused by the use of alteplase treatment. Hence, the associated risk of side effects is estimated to hinder market growth in the coming years.
• Low Awareness Among People in Emerging Nations Regarding the Cerebral Infarction
• Inadequacy of Preclinical Testing in Emerging Nations